NCT01625195 · COMPLETED

Causal Relationships Between LC-omega-3-enriched Diet and Cognition

This trial is testing whether a diet enriched with long-chain omega-3 fatty acids improves cognition in adults aged 20 to 80. Researchers are measuring effects on memory, verbal fluency, and visuospatial skills in a randomized, double-blind, placebo-controlled design — meaning neither participants nor researchers know who gets the real supplement. This is a Phase NA study, meaning it is a nutritional investigation rather than a standard drug trial phase.

You may qualify if

  • male and female subjects aged between 20-80 years old

You're excluded if

  • tobacco use,
  • malnutrition (assessed from blood albumin, hemoglobin and lipids),
  • subjects taking an EPA+DHA supplement for more than one month,
  • swallowing problems,
  • severe gastro-intestinal problems,
  • diabetes,
  • uncontrolled thyroid disease,
  • severe renal failure,
  • liver disease or any other endocrine disorder,
  • medication that would affect lipoprotein metabolism,
  • chronic immune condition or inflammation (CRP > 10 mg/l, white cell count),
  • cancer,
  • recent major surgery or cardiac event,
  • pregnant or lactating women,
  • uncorrected visual or hearing problems,
  • dementia,
  • ongoing or past severe drug or alcohol abuse,
  • psychiatric difficulties or depression, and
  • ongoing or past intensive physical training

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2020-05-08

View full record on ClinicalTrials.gov

All APOE4 clinical trials